Candace Cameron Bure Provides Update on Dave Coulier's Health During His Cancer Battle
February 9, 2025 - 00:26
In a heartfelt conversation at the 32nd Annual Movieguide Awards, Candace Cameron Bure shared insights about her longtime friend and 'Full House' co-star, Dave Coulier. She revealed that she frequently reaches out to Coulier, who is currently undergoing treatment for stage 3 non-Hodgkin lymphoma, a diagnosis he received in October 2024.
Bure expressed her admiration for Coulier's resilience during this challenging time, emphasizing that he remains optimistic and strong as he navigates his recovery journey. The support from friends and family has been crucial for Coulier, and Bure's regular check-ins serve as a reminder of their enduring bond.
As fans continue to rally behind him, Bure's updates bring a sense of hope and solidarity. The entertainment community stands united in sending positive thoughts and prayers for Coulier's health and well-being as he fights this battle with courage and determination.
MORE NEWS
November 10, 2026 - 23:38
Health Insurance Tips Gaining Popularity Among Young FreelancersRecent data suggests that it`s a trend on the rise over the last half decade. Freelancers from Gen Z and millennial generations are increasingly utilizing a specific health insurance strategy that...
November 10, 2026 - 05:58
Supporting Veterans' Health Needs Ahead of Veteran's DayWith Veteran`s Day coming up on Wednesday, it`s a chance to recognize the men and women who have served our country. As the nation prepares to honor these heroes, discussions are intensifying...
November 9, 2026 - 10:33
CVS' Split into Two Fails to Address Core IssuesCVS Health`s recent decision to split into two separate entities has sparked considerable debate among industry experts. While the move aims to streamline operations and enhance focus, it does not...
November 8, 2026 - 19:26
How to Disable Google Health's AI Coach FeatureIf you find Google Health`s AI Coach feature bothersome, there`s a simple way to turn it off. Many users appreciate the insights and guidance offered by this premium tool, but not everyone is a fan...